BD2Decide aimed to develop a more precise prognostic prediction than the ones currently used in Cancers of Head and Neck Region (HNC), which targeted to implement the first-line treatment in order to maximise the therapeutic results and minimise the impacts of HNC therapy. Currently, the adopted treatment decision method is based on prognostic systems, which consider only a few risk factors and result in late diagnosis of relevant cases in an advanced Stage.
BD2Decide introduced a Decision Support System (DSS), which provided clinicians with the “means” and all the necessary information to tailor treatment and care delivery pathway to each and any HNC patient during their usual practice, in contrast to current “one-size-fits-all approach”. This project, co-funded by the EU under the H2020-PHC-2015 program, realized and validated an Integrated Decision Support System that linked population-specific epidemiology and behavioral data, patient-specific genomic, pathology, clinical and imaging data with big data techniques, multi-scale prognostic models.
BD2Decide improved the clinical decision process, uncovered new patient-specific patterns that could improve care, and created a virtuous circle of learning. A multi-centric clinical study with more than 1.000 patients was used to validate the system.
The BD2Decide Consortium was coordinated by Azienda Ospedaliero-Universitaria di Parma (Italy) and consisted of Universidad Politecnica de Madrid (Spain), as the technical leader, Stichting Vu-Vumc (the Netherlands), Heinrich-Heineuniversitaet Duesseldorf Udus (Germany), Fondazione IRCCS Istituto Nazionale dei Tumori (Italy), Fraunhofer Gesellschaft Zur Forderung der Angewandten Forschung Ev (Germany), Athens Technology Center SA (Greece), ALL-IN-IMAGE LTD (Israel), Stichting Maastricht Radiation Oncology MAASTRO Clinic (the Netherlands), Politecnico di Milano (Italy), Multimed Engineers SRL (Italy) and Universita Degli Studi di Parma (Italy).
ATC was leading the development of advanced graphical visualization tools for prognostic data disclosure and patient co-participation to the selected treatment.
The project started in January 2016 and had a duration of 45 months.
